These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10254209)

  • 1. Point of law: what are the legal implications of prescribing and administering FDA-approved drugs in nonapproved ways?
    Kaunitz AM
    Hosp Med Staff; 1982 Feb; 11(2):15-8. PubMed ID: 10254209
    [No Abstract]   [Full Text] [Related]  

  • 2. Legal implications of preparing and dispensing approved drugs for unlabeled indications.
    Podell LB
    Am J Hosp Pharm; 1983 Jan; 40(1):111-3. PubMed ID: 6823981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approved drugs used in a nonapproved way.
    Kasik JE; Solomons G
    J Iowa Med Soc; 1980 Nov; 70(11):476-8. PubMed ID: 7441028
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of approved drugs in a nonapproved way.
    Kasik JE
    Iowa Med; 1987 Oct; 77(10):513-5. PubMed ID: 3679770
    [No Abstract]   [Full Text] [Related]  

  • 5. Legal implications of preparing and dispensing drugs under conditions not in a product's official labeling.
    Mandl FL; Greenberg RB
    Am J Hosp Pharm; 1976 Aug; 33(8):814-6. PubMed ID: 949065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are drugs approved by the FDA safe and risk free?
    Natl Med Leg J; 1991; 2(1):8. PubMed ID: 2018814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Package inserts, adverse drug reactions, and the physician's liability.
    Morrell MX
    Ration Drug Ther; 1975 Aug; 9(8):1-6. PubMed ID: 1144773
    [No Abstract]   [Full Text] [Related]  

  • 8. Black box warnings in prescription drug labeling: results of a survey of 206 drugs.
    Beach JE; Faich GA; Bormel FG; Sasinowski FJ
    Food Drug Law J; 1998; 53(3):403-11. PubMed ID: 10346718
    [No Abstract]   [Full Text] [Related]  

  • 9. Adherence to approved drug use as a predictor of length of hospital stay.
    Gibson JT; Idsvoog P
    Am J Hosp Pharm; 1975 Mar; 32(3):280-2. PubMed ID: 1136975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA reform in Congress: AIDS community absent. Food and Drug Administration.
    James JS
    AIDS Treat News; 1995 Apr; (no 220):4-5. PubMed ID: 11362320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA extra-label restriction on drugs.
    Varney JE
    J Am Vet Med Assoc; 1983 Dec; 183(12):1372, 1374-5. PubMed ID: 6654717
    [No Abstract]   [Full Text] [Related]  

  • 12. The medico-legal aspects of drug interactions.
    Goldstein EM
    J Forensic Sci; 1973 Oct; 18(4):335-43. PubMed ID: 4784302
    [No Abstract]   [Full Text] [Related]  

  • 13. Sources of drug information: FDA-approved labeling and other official FDA sources.
    Lindstrom JA
    Dermatol Ther; 2009; 22(3):246-56. PubMed ID: 19453349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 15. Selected item from the FDA drug bulletin. Use of drugs for unapproved indications: legal responsibility.
    Calif Med; 1972 Dec; 117(6):80-1. PubMed ID: 4635407
    [No Abstract]   [Full Text] [Related]  

  • 16. From off-label prescribing towards a new FDA.
    Tabarrok A
    Med Hypotheses; 2009 Jan; 72(1):11-3. PubMed ID: 18835103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA paves the way for drug law reform.
    Eichelberger BM
    Am J Hosp Pharm; 1978 Jul; 35(7):878, 882. PubMed ID: 665706
    [No Abstract]   [Full Text] [Related]  

  • 18. Sounding board. Creative tension: FDA and medicine.
    Kennedy D
    N Engl J Med; 1978 Apr; 298(15):846-50. PubMed ID: 345121
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.